fluoxetine has been researched along with Down Syndrome in 13 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
Down Syndrome: A chromosome disorder associated either with an extra chromosome 21 or an effective trisomy for chromosome 21. Clinical manifestations include hypotonia, short stature, brachycephaly, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, Simian crease, and moderate to severe INTELLECTUAL DISABILITY. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with fluoxetine fully restored all these defects." | 5.39 | Early pharmacotherapy with fluoxetine rescues dendritic pathology in the Ts65Dn mouse model of down syndrome. ( Bartesaghi, R; Bianchi, P; Calzà, L; Ciani, E; Grossi, G; Guidi, S; Mangano, C; Ragazzi, E; Stagni, F; Trazzi, S, 2013) |
| "Down syndrome is caused by triplication of chromosome 21 and is associated with neurocognitive phenotypes ranging from severe intellectual disability to various patterns of more selective neuropsychological deficits, including memory impairments." | 5.38 | Adult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome. ( Ehninger, D; Heinen, M; Hettich, MM; Paesler, K; Ryan, DP; Schnell, S, 2012) |
| "Depressive illness in a patient with Down's syndrome and autism responded to fluoxetine." | 3.68 | Depression in autistic disorder. ( Ghaziuddin, M; Tsai, L, 1991) |
| "Down syndrome affects more than 5 million people globally." | 2.50 | Prenatal treatment of Down syndrome: a reality? ( Bianchi, DW; Delabar, JM; Guedj, F, 2014) |
| "Trisomy 21 was first described as a syndrome in the middle of the nineteenth century and associated to a chromosomic anomaly one hundred years later: the most salient feature of this syndrome is a mental retardation of variable intensity." | 2.46 | [New perspectives on molecular and genic therapies in Down syndrome]. ( Delabar, JM, 2010) |
| "Treatment with fluoxetine fully restored all these defects." | 1.39 | Early pharmacotherapy with fluoxetine rescues dendritic pathology in the Ts65Dn mouse model of down syndrome. ( Bartesaghi, R; Bianchi, P; Calzà, L; Ciani, E; Grossi, G; Guidi, S; Mangano, C; Ragazzi, E; Stagni, F; Trazzi, S, 2013) |
| "Down syndrome is caused by triplication of chromosome 21 and is associated with neurocognitive phenotypes ranging from severe intellectual disability to various patterns of more selective neuropsychological deficits, including memory impairments." | 1.38 | Adult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome. ( Ehninger, D; Heinen, M; Hettich, MM; Paesler, K; Ryan, DP; Schnell, S, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 11 (84.62) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stagni, F | 4 |
| Magistretti, J | 1 |
| Guidi, S | 5 |
| Ciani, E | 5 |
| Mangano, C | 2 |
| Calzà, L | 4 |
| Bartesaghi, R | 5 |
| Begenisic, T | 1 |
| Baroncelli, L | 1 |
| Sansevero, G | 1 |
| Milanese, M | 1 |
| Bonifacino, T | 1 |
| Bonanno, G | 1 |
| Cioni, G | 1 |
| Maffei, L | 1 |
| Sale, A | 1 |
| Bianchi, P | 3 |
| Giacomini, A | 2 |
| De Franceschi, M | 1 |
| Moldrich, R | 1 |
| Kurniawan, N | 1 |
| Mardon, K | 1 |
| Giuliani, A | 2 |
| Guedj, F | 1 |
| Bianchi, DW | 1 |
| Delabar, JM | 2 |
| Ragazzi, E | 2 |
| Filonzi, M | 1 |
| De Iasio, R | 1 |
| Rimondini, R | 1 |
| Pekrul, SR | 1 |
| Fitzgerald, KD | 1 |
| Kuehn, BM | 1 |
| Trazzi, S | 2 |
| Felice, D | 1 |
| Grossi, G | 2 |
| Fernandez, M | 1 |
| Heinen, M | 1 |
| Hettich, MM | 1 |
| Ryan, DP | 1 |
| Schnell, S | 1 |
| Paesler, K | 1 |
| Ehninger, D | 1 |
| Clark, S | 1 |
| Schwalbe, J | 1 |
| Stasko, MR | 1 |
| Yarowsky, PJ | 1 |
| Costa, AC | 1 |
| Ghaziuddin, M | 1 |
| Tsai, L | 1 |
2 reviews available for fluoxetine and Down Syndrome
| Article | Year |
|---|---|
Prenatal treatment of Down syndrome: a reality?
Topics: Animals; Animals, Newborn; Apigenin; Catechin; Choline; Disease Models, Animal; Down Syndrome; Dyrk | 2014 |
[New perspectives on molecular and genic therapies in Down syndrome].
Topics: Animals; Catechin; Chromosomes, Human, Pair 21; Disease Models, Animal; Down Syndrome; Droxidopa; Dr | 2010 |
11 other studies available for fluoxetine and Down Syndrome
| Article | Year |
|---|---|
Pharmacotherapy with fluoxetine restores functional connectivity from the dentate gyrus to field CA3 in the Ts65Dn mouse model of down syndrome.
Topics: Animals; Brain-Derived Neurotrophic Factor; CA3 Region, Hippocampal; Dendritic Spines; Dentate Gyrus | 2013 |
Fluoxetine in adulthood normalizes GABA release and rescues hippocampal synaptic plasticity and spatial memory in a mouse model of Down syndrome.
Topics: Analysis of Variance; Animals; Antidepressive Agents, Second-Generation; Biophysics; Disease Models, | 2014 |
Prenatal pharmacotherapy rescues brain development in a Down's syndrome mouse model.
Topics: Animals; Animals, Newborn; Brain; Cell Proliferation; Disease Models, Animal; Down Syndrome; Female; | 2014 |
Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice.
Topics: Alzheimer Disease; Animals; Animals, Newborn; Cognition; Dendrites; Disease Models, Animal; Down Syn | 2015 |
Memantine Augmentation in a Down's Syndrome Adolescent with Treatment- Resistant Obsessive-Compulsive Disorder.
Topics: Adolescent; Down Syndrome; Drug Synergism; Excitatory Amino Acid Antagonists; Fluoxetine; Humans; Ma | 2015 |
Treating trisomies: Prenatal Down's syndrome therapies explored in mice.
Topics: Animals; Brain; Disease Models, Animal; Down Syndrome; Fetal Therapies; Fluoxetine; Mice; Selective | 2016 |
Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome.
Topics: Animals; Animals, Newborn; Brain; Brain-Derived Neurotrophic Factor; Cell Proliferation; Cognition; | 2010 |
Early pharmacotherapy with fluoxetine rescues dendritic pathology in the Ts65Dn mouse model of down syndrome.
Topics: Animals; Cell Proliferation; Dendrites; Dendritic Spines; Disease Models, Animal; Down Syndrome; Flu | 2013 |
Adult-onset fluoxetine treatment does not improve behavioral impairments and may have adverse effects on the Ts65Dn mouse model of Down syndrome.
Topics: Animals; Behavior, Animal; Body Weight; Cell Count; Cognition Disorders; Down Syndrome; Female; Fluo | 2012 |
Fluoxetine rescues deficient neurogenesis in hippocampus of the Ts65Dn mouse model for Down syndrome.
Topics: Animals; Cell Differentiation; Disease Models, Animal; Down Syndrome; Female; Fluoxetine; Hippocampu | 2006 |
Depression in autistic disorder.
Topics: Adolescent; Arousal; Autistic Disorder; Depressive Disorder; Down Syndrome; Fluoxetine; Humans; Male | 1991 |